N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage
- PMID: 1599440
- PMCID: PMC1132679
- DOI: 10.1042/bj2840589
N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage
Abstract
Bovine articular cartilage was cultured both in the presence and in the absence of human recombinant interleukin-1 alpha (IL-1) (100 units/ml). Addition of this cytokine stimulated matrix degradation approx. 3-fold. This increased degradation permitted characterization of the large chondroitin sulphate proteoglycan (aggrecan) fragments accumulating in the media. When compared with controls, the proteoglycans isolated from the medium of cultures treated with IL-1 exhibited a decrease in the Kav. (control 0.25; IL-1-treated 0.37), determined by Sepharose CL-2B chromatography. This decrease in proteoglycan size was accompanied by a decreased ability of these monomers to associate with hyaluronic acid. Thus only 20% of the proteoglycans isolated from the medium of IL-1-treated cultures, compared with 39% for control cultures, had the capacity to form high-M(r) aggregates with hyaluronic acid. SDS/PAGE analysis of the proteoglycans from the media of IL-1-treated cultures demonstrated several large proteoglycan protein-core bands (M(r) 144,000-380,000). The protein-core bands with M(r) 144,000-266,000 exhibited a significantly decreased reactivity with monoclonal antibody 1-C-6 (specific for domains G1 and G2). The N-terminal amino acid sequence of four of these protein-core bands (M(r) 144,000, 173,000, 214,000 and 266,000) yielded sequences LGQRPPV-Y-PQLF(E), AGEGP(S)GILEL-GAP(S)-AP(D)M, GLG-VEL-LPGE and (A)RGSVIL-AKPDFEV-P-A. A comparison of these N-terminal amino acid sequences with the published proteoglycan sequence for bovine nasal cartilage [Oldberg, Antonsson & Heinegård (1987) Biochem. J. 243, 255-259], rat chondrosarcoma [Doege, Sasaki, Horigan, Hassell & Yamada (1987) J. Biol. Chem. 262, 17757-17769] and human articular cartilage [Doege, Sasaki, Kimura & Yamada (1991) J. Biol. Chem. 266, 894-902] permitted assignment of their relative positions on the core protein. Furthermore, on the basis of this similarity to published sequence, putative sites of enzymic cleavage were constructed. These theoretical cleavage sites revealed a glutamic acid residue in the P1 position and an uncharged polar or non-polar residue in the P1' position.
Similar articles
-
Catabolism of aggrecan by explant cultures of human articular cartilage in the presence of retinoic acid.Arch Biochem Biophys. 1995 Sep 10;322(1):22-30. doi: 10.1006/abbi.1995.1431. Arch Biochem Biophys. 1995. PMID: 7574678
-
Mechanism of catabolism of aggrecan by articular cartilage.Arch Biochem Biophys. 1992 Apr;294(1):115-22. doi: 10.1016/0003-9861(92)90144-l. Arch Biochem Biophys. 1992. PMID: 1550337
-
Characterization of proteoglycans isolated from associative extracts of human articular cartilage.Biochem J. 1993 Jul 1;293 ( Pt 1)(Pt 1):165-72. doi: 10.1042/bj2930165. Biochem J. 1993. PMID: 8328959 Free PMC article.
-
The structure, function and turnover of aggrecan, the large aggregating proteoglycan from cartilage.Eur J Clin Chem Clin Biochem. 1994 Apr;32(4):249-57. Eur J Clin Chem Clin Biochem. 1994. PMID: 8038265 Review.
-
The link proteins.Experientia. 1993 May 15;49(5):393-402. doi: 10.1007/BF01923584. Experientia. 1993. PMID: 8500595 Review.
Cited by
-
The intermediates of aggrecanase-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1.Biochem J. 2000 Oct 1;351(Pt 1):161-6. doi: 10.1042/0264-6021:3510161. Biochem J. 2000. PMID: 10998358 Free PMC article.
-
Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy?Clin Mol Pathol. 1995 Aug;48(4):M167-77. doi: 10.1136/mp.48.4.m167. Clin Mol Pathol. 1995. PMID: 16696000 Free PMC article. No abstract available.
-
Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.J Clin Invest. 1997 Jul 1;100(1):93-106. doi: 10.1172/JCI119526. J Clin Invest. 1997. PMID: 9202061 Free PMC article.
-
Variations in aggrecan structure modulate its susceptibility to aggrecanases.Biochem J. 2003 Oct 1;375(Pt 1):183-9. doi: 10.1042/BJ20030609. Biochem J. 2003. PMID: 12859252 Free PMC article.
-
Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.Biochem J. 1995 Feb 1;305 ( Pt 3)(Pt 3):799-804. doi: 10.1042/bj3050799. Biochem J. 1995. PMID: 7531436 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous